Zobrazeno 1 - 10
of 321
pro vyhledávání: '"Akihito Tsuji"'
Autor:
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Purpose Although early tumor shrinkage (ETS) is a predictor of improved overall survival (OS), the association between ETS and health-related quality of life (HRQOL) remains unclear for patients with metastatic colorectal cancer (mCRC) treat
Externí odkaz:
https://doaj.org/article/8e277a2749b9411aa5325e80e6e2203a
Autor:
Makoto Ueno, Chigusa Morizane, Masayuki Furukawa, Daisuke Sakai, Yoshito Komatsu, Yousuke Nakai, Masahiro Tsuda, Masato Ozaka, Nobumasa Mizuno, Manabu Muto, Akira Fukutomi, Masafumi Ikeda, Akihito Tsuji, Akio Katanuma, Toshikazu Moriwaki, Takeshi Kajiwara, Hiroshi Ishii, Yuji Negoro, Satoshi Shimizu, Noriko Nemoto, Shingo Kobayashi, Keigo Makino, Junji Furuse
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 2088-2099 (2021)
Abstract Purpose Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase inhibitor. Such inhibitors increase sensitivity to fluorouracil, the active form o
Externí odkaz:
https://doaj.org/article/e0445e9649c546018114eb63c08c8a74
Autor:
Hironaga Satake, Koji Ando, Eiji Oki, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Masaki Mori
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combin
Externí odkaz:
https://doaj.org/article/c60e1d3ac27b4918a6f12db6c2a7c54a
Autor:
Masaaki Miyo, Takeshi Kato, Takayuki Yoshino, Takeharu Yamanaka, Hideaki Bando, Hironaga Satake, Kentaro Yamazaki, Hiroya Taniguchi, Eiji Oki, Masahito Kotaka, Koji Oba, Yoshinori Miyata, Kei Muro, Yoshito Komatsu, Hideo Baba, Akihito Tsuji
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarr
Externí odkaz:
https://doaj.org/article/9f5f603163384f26bfa0d89bb5bf4e2c
Autor:
Akira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 5, Pp 1779-1789 (2020)
Abstract Background It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with th
Externí odkaz:
https://doaj.org/article/17e4563d1d4c4391ab789022af8e5e46
Autor:
Daisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, Asumi Kaneko, Yoshiaki Nakamura, Akihito Kawazoe, Hideaki Bando, Hiroya Taniguchi, Kohei Shitara, Takashi Kojima, Akihito Tsuji, Takayuki Yoshino
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retro
Externí odkaz:
https://doaj.org/article/5353642cd7e043c7a448adae57648b7d
Autor:
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. Methods Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regime
Externí odkaz:
https://doaj.org/article/6bb077a4afc0401982a619dd6d4c130c
Autor:
Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Sudo, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi
Publikováno v:
Cancer Medicine, Vol 7, Iss 9, Pp 4217-4227 (2018)
Abstract A prospective trial has not been performed to investigate associations between quality of life (QOL), adverse events (AEs), and overall survival (OS) in the first‐line treatment with cetuximab plus standard chemotherapy for advanced/metast
Externí odkaz:
https://doaj.org/article/752e48f504594ec88fe13ab55e417cca
Autor:
Misato Ogata, Masahito Kotaka, Takatsugu Ogata, Yukimasa Hatachi, Hisateru Yasui, Takeshi Kato, Akihito Tsuji, Hironaga Satake
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234314 (2020)
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients
Externí odkaz:
https://doaj.org/article/e1f1577bf5554925bebe0578946c2bc5
Autor:
Tsutomu Namikawa, Hiromichi Maeda, Hiroyuki Kitagawa, Koji Oba, Akihito Tsuji, Takaki Yoshikawa, Michiya Kobayashi, Kazuhiro Hanazaki
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
Abstract Background Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is
Externí odkaz:
https://doaj.org/article/b1848eade5cd4718b837d1b13835e91b